Switching beta-blocker therapy in chronic heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Long-acting beta-blockers improve survival in heart failure, unlike short-acting ones.
• Short-acting beta-blockers have shown less favorable survival outcomes.

Purpose of the Study:

• To assess the safety of switching from short-acting metoprolol to long-acting bisoprolol.
• To evaluate this switch in patients with heart failure and impaired left ventricular systolic function post-myocardial infarction.

Main Methods:

• Enrolled 282 patients with NYHA classes I-III heart failure and/or reduced ejection fraction.
• Discontinued metoprolol 12 hours prior to initiating bisoprolol therapy.
• Administered bisoprolol doses ranging from 2.5 mg to 10 mg, with 28.5% reaching the target dose.

Main Results:

• Mean heart rate decreased from 84 bpm to 67 bpm post-switch.
• Dosage titration varied, with many patients on lower doses than the 10 mg target.
• The switch was successfully managed in a large cohort of heart failure patients.

Conclusions:

• Switching stable heart failure patients from short-acting to long-acting beta-blockers is safe.
• The observed heart rate reduction suggests enhanced adrenergic blockade with bisoprolol.
• Physician-guided dose titration to the maximum target dose was achieved in only about one-third of patients.